Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO101 topical gel versus placebo for antimicrobial treatment of post-curettage wounds
ACTRN12607000448448Phase 2Active, not recruiting
- Sponsor
- Neosil
- Start
- Sep 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NEO101 in wound colonization (2 arms), sponsored by Neosil. Primary endpoint: Safety and local tolerability of NEO101 gel. Started Sep 2007; status: active, not recruiting.
02
Drugs
NEO101
03
Conditions
wound colonization
Beyond the preview
Go deeper on ACTRN12607000448448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000448448.